Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
working closely with the U.S. Food and Drug Administration to evaluate our potential next steps relating to patent foramen ovale (PFO) treatment for the stroke and transient ischemic attack (TIA) indications.
http://ih.advfn.com/p.php?pid=nmona&article=45903874
!! Kabooom !!
NMT Medical Announces New $2 Million Credit Facility
Date : 01/06/2011 @ 7:30AM
Source : MarketWire
Stock : NMT Medical (NMTI)
http://ih.advfn.com/p.php?pid=nmona&article=45903874
NMT Medical, Inc. (NASDAQ: NMTI) today announced that it has entered into a credit agreement with LSQ Funding Group, L.C., a Florida-based firm that specializes in providing financing to small- and medium-sized businesses.
The asset-based credit facility provides for borrowings up to $2 million for working capital requirements and other general corporate purposes. The credit facility has a one-year term and is subject to a borrowing base calculated as a percentage of domestic accounts receivable that are pledged as collateral against the loan.
Richard E. Davis, NMT's Chairman, President and Chief Executive Officer, said, "This non-equity based credit facility, which replaces the credit arrangement with Silicon Valley Bank that we recently terminated, provides NMT with the necessary working capital required to fund its ongoing operations. We continue to tightly manage our expenses while working closely with the U.S. Food and Drug Administration to evaluate our potential next steps relating to patent foramen ovale (PFO) treatment for the stroke and transient ischemic attack (TIA) indications. In addition, we are continuing to evaluate all strategic options."
About NMT Medical, Inc.
NMT Medical is an advanced medical technology company that designs, develops, manufactures and markets proprietary implant technologies that allow interventional cardiologists to treat structural heart disease through minimally invasive, catheter-based procedures. NMT is currently investigating the potential connection between a common heart defect that allows a right-to-left shunt or flow of blood through a defect like a patent foramen ovale (PFO) and brain attacks such as embolic stroke, transient ischemic attacks (TIAs) and migraine headaches. A common right-to-left shunt can allow venous blood, unfiltered and unmanaged by the lungs, to enter the arterial circulation of the brain, possibly triggering a cerebral event or brain attack. More than 34,000 PFOs have been treated globally with NMT's minimally invasive, catheter-based implant technology.
For more information about NMT Medical, please visit www.nmtmedical.com.
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements, including those relating to the Company's cash position and next steps relating to patent foramen ovale (PFO) treatment for the stroke and transient ischemic attack (TIA) indications, involve known and unknown risks, uncertainties or other factors that may cause actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Factors that might cause such a difference include, but are not limited to, those discussed under the heading "Risk Factors" included in the Management's Discussion and Analysis of Financial Condition and Results of Operations in the Company's Annual Report on Form 10-K for the year ended December 31, 2009, Quarterly Report on Form 10-Q for the quarter ended September 30, 2010, and subsequent filings with the U.S. Securities and Exchange Commission.
Contact:
Richard E. Davis
Chief Executive Officer
NMT Medical, Inc.
(617) 737-0930
this is going to run this week. high volume, great charts.
if NMTI hits this with an good PR, its going off
SmarTrend's Trend Spotter See Continued Upward Momentum on Shares of NMT Medical (NMTI)
Written on Mon, 01/03/2011 - 10:03am
By Chip Brian
http://www.mysmartrend.com/news-briefs/technical-analysis/smartrends-trend-spotter-see-continued-upward-momentum-shares-nmt-med
SmarTrend is monitoring the recent change of momentum in NMT Medical. Please refer to our Company Overview for the results of our proprietary technical indicators that have been scanning shares of NMT Medical in search of a potential trend change.
In the past 52 weeks, shares of NMT Medical have traded between a low of $0.20 and a high of $4.99 and are now at $0.42, which is 109% above that low price.
NMT Medical is currently above its 50-day moving average of $0.28 and should find resistance at its 200-day moving average of $1.43. Look for these moving averages to climb to confirm the company's upward momentum.
In the last five trading sessions, the 50-day MA has fallen 0.56% while the 200-day MA has slid 5.21%.
SmarTrend will continue to scan these moving averages and a number of other proprietary indicators for any shifts in the trajectory of NMT Medical shares.
chart review below. disclaimer: i do not currently own shares and am posting here by request from another user.
the chart looks weak. can never ignore bad news. i did not do much dd other than to check why it fell. if anyone knows of other potential products that may save pps that would be good as pps is below all supports. until it regains any support, the closest is around .58, this is very very risky at best.
the monthly shows it is still headed down. there is some hesitation on the chart but that may be due to there being little in the way of down to go.
the weekly may be ready to go up, though the move looks weak atm. could make a line break by early september. however flat charts are scary and hard to predict.
same can be said of the daily. you want to see some volatility, not apathy. point being pps has been in an upward move since mid july... yet it can not flip psar which has flatlined at .50, .49 today. if it doesnt flip by the end of the week that is a bad sign.
there is some weak support just over .40 so if it can ride this channel until september it may flip then and get a pop.
the hourly chart really tells us nothing as pps is so flat. channels do not hold.
so if it can stay above .40 by september it may have a chance to pop, will check it again. initial target would be between 1 and 1.10 as some resistance begins here and the monthly support line is here. gaining that would be good. if so it could fight its way back to the big 1.90/1.95 resistance. but first it needs to crack that .58/.60 line.
right now a risk play is buying low .40s and selling for 20% or so on a pop. if all looks good by september getting in when its breaking a channel around that .60 mark and trying for 1 would work but some news may be needed for this. definitely need some good news to make that 1.90 mark.
if the posts about a potential r/s are more than just rumor and conjecture that may expedite these numbers, but not in a good way...
gl all
That's a good point but hopefully this one will break $1 with news and not a RS. We'll see what happens. I'm actually surprised that .4553 has been the low so far today.
...they've got to get back to $1... " True, and as you suggest, I hope they'll climb back up there by announcing positive developments.
However, unfortunately, small companies like this have a habit of meeting the listing requirement by doing a reverse split.
FWIW, averaged down some today. GLTA.
Well from the public earnings call, it sounds as if October might be the magical month. Also, they've got to get back to $1 to maintain Nasdaq listing requirements. That's and added incentive for them to post positive news soon.
IMO no.
But if it does I'll be going on a buying spree!
Think I've flipped this over a dozen times.
Keeping a pretty good core as I still think it's WAY too low.
Still looking for it to go a buck at least, but when?
auroradude
Are we going to touch $.40 again?
Yeah, I've been flipping it between the 47-54 range but am holding now. I think that $2-$4 definitely sounds fair. I got the vibe from their conference call a few days ago that October should be a big month for them.
Without a doubt.
NMT Medical, Inc. - Q2/2010 Earnings Call Transcript
July 30, 2010
http://seekingalpha.com/article/217735-nmt-medical-inc-q2-2010-earnings-call-transcript?source=feed
I thought that the conference call went really well today. Did anyone else from here attend? It sounds as if they have a solid plan and I really hope that their next phase of trials goes well but it sounds like the company is solid enough to quickly rebound anyway with all of the exposure in Europe, etc.
NMT Medical Announces Second-Quarter 2010 Financial Results
Date : 07/29/2010 @ 7:30AM
Source : Business Wire
Stock : NMT Medical, Inc. (NMTI)
http://ih.advfn.com/p.php?pid=nmona&article=43794356&symbol=NMTI
NMT Medical, Inc. (NASDAQ: NMTI), an advanced medical technology company that designs, develops, manufactures and markets proprietary implant technologies that allow interventional cardiologists to treat structural heart disease through minimally invasive, catheter-based procedures, today announced financial results for the quarter ended June 30, 2010.
Second-Quarter Results
Second-quarter 2010 total revenues were approximately $2.6 million compared with approximately $3.2 million for the quarter ended June 30, 2009.
Cardiac septal repair implant sales in North America for the second quarter of 2010 were approximately $1.9 million compared with approximately $2.4 million in the second quarter of 2009. Implant sales outside of North America were approximately $700,000 in the second quarter of 2010 compared with $800,000 in the corresponding period of 2009.
For the second quarter of 2010, NMT reported net income of approximately $2.6 million, or $0.16 per diluted share, compared with a net loss of approximately $3.8 million, or $0.29 per share, for the corresponding period in 2009. Net income for the second quarter of 2010 includes a non-cash, pre-tax gain of $6.4 million related to the change in fair value of the warrants issued in February 2010 as part of the Company’s $5.8 million financing. For the second-quarter of 2010, NMT reported a loss from operations of approximately $4.0 million compared with a loss of approximately $3.9 million in the same period of 2009.
Management Comments
“During the second quarter, we believe the medical community was eagerly anticipating the results of CLOSURE I, our pivotal patent foramen ovale (PFO)/stroke and transient ischemic attack (TIA) trial, which may have slowed the referral pattern and the number of procedures performed during the second quarter in the U.S.,” said President and Chief Executive Officer Frank Martin. “In addition, our revenues outside of North America reflect a shortfall in our larger Western European markets.”
“We commenced data analysis for CLOSURE I early in the quarter and announced preliminary results in mid-June, which indicated that the trial did not meet its primary endpoint,” Martin said. “However, the preliminary results of CLOSURE I did confirm several positive attributes of our technology. While the trial did not demonstrate that treatment by device closure with the STARFlex® implant is superior, the results indicate that closure with STARFlex® provided a small, but not statistically significant, benefit over current best medical therapy. The primary endpoint included the incidence of a recurrent stroke/TIA confirmed by MRI imaging. In addition to a very low rate of thrombus formation, for the first time in any prospective, randomized and independent core lab adjudicated PFO related trial, the results indicate that the safety profile of the STARFlex® device had a low rate of complications, similar to that of current best medical therapy. Closure rates in the trial were 86.5%, which is consistent with NMT’s previously reported results for the STARFlex® implant. We are currently in discussions with the U.S. Food and Drug Administration to evaluate our possible next steps relating to the stroke/TIA indication. We plan to provide an update, once an appropriate course of action has been determined. We currently anticipate that full trial data results will be discussed at the American Heart Association meeting in November 2010.”
Chief Operating Officer, Richard E. Davis, said, “As of June 30, 2010, cash, cash equivalents and marketable securities were approximately $6.5 million. Going forward, we will continue to tightly manage expenses, preserve cash, evaluate financing alternatives and adjust our operating plan accordingly in order to support our ongoing clinical trials and development programs. We currently expect third-quarter 2010 revenues to be approximately $2.5 million.”
Conference Call Reminder
Management will conduct a conference call at 9:30 a.m. ET today to review the Company’s financial results and provide a business update. Individuals who are interested in listening to the live webcast should log on to the “Investors” section of NMT Medical’s website at www.nmtmedical.com. The conference call also may be accessed by dialing (877) 407-5790 or (201) 689-8328. For interested individuals unable to join the live conference call, a replay will be archived for one year via webcast on the Company’s website.
About NMT Medical, Inc.
NMT Medical is an advanced medical technology company that designs, develops, manufactures and markets proprietary implant technologies that allow interventional cardiologists to treat structural heart disease through minimally invasive, catheter-based procedures. NMT is currently investigating the potential connection between a common heart defect that allows a right-to-left shunt or flow of blood through a defect like a patent foramen ovale (PFO) and brain attacks such as embolic stroke, transient ischemic attacks (TIAs) and migraine headaches. A common right-to-left shunt can allow venous blood, unfiltered and unmanaged by the lungs, to enter the arterial circulation of the brain, possibly triggering a cerebral event or brain attack. More than 33,000 PFOs have been treated globally with NMT's minimally invasive, catheter-based implant technology.
For more information about NMT Medical, please visit www.nmtmedical.com.
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements – including statements regarding the timing, cost, clinical status, and outcome of the Company’s CLOSURE I trial, its ongoing clinical trials and development programs, the Company’s revenue expectations for the third quarter of 2010, the Company’s expected savings from cost reductions, the success of its new distribution partnerships, expansion of the Company’s cardiovascular business and market opportunities, including stroke, TIA and any other new applications for the Company’s technology or products, regulatory approvals for the Company’s products in the United States and abroad and the Company’s investment in product development – involve known and unknown risks, uncertainties or other factors that may cause actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Factors that may cause such a difference include, but are not limited to, the Company’s ability to develop and commercialize new products, a potential delay in the regulatory process with the U.S. Food and Drug Administration and foreign regulatory agencies, as well as risk factors discussed under the heading “Risk Factors” included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2009, Form 10-Q for the quarter ended March 31, 2010 and subsequent filings with the U.S. Securities and Exchange Commission.
I got back in today at .4785. Any idea what we might expect from the earnings Thursday morning? I'm contemplating whether I want to flip again tomorrow or hold until Thursday.
ALWAYS good to ring the bell!!!
Congrats!
I exited today for small gain.
Wide swings on NMTI...even AH!
Great for flippin', and IMO a good one for the rest of the year.
GL
edit: love the clash!
Na. I didn't put enough in to flip it effectively. Looking for mid-hold. Although, if I can free up some capital. I'll be looking to add on a dip. Wanted some at .475 and was close to picking it up today.
LOL! Sometimes they just disappear..
Hey scoot - you flippin' this at all?
ladadeedaaaaaaa. Is a positive close too much to ask for?
Just covered a morning flip.
Such a good one to flip and reinvest into NMTI stock.
Still looking for big run into end of year...
Hopefully this upward trend will continue, in anticipation of the financials next week!
Started small position yesterday at .46
The sell off was too dramatic - WAY overdone.
Hope we are right...holding more than current volume so far today...don't see much risk besides opportunity costs...time will tell
EDIT - hope we get a good report next week$$$
AD!! sounds good - it's a great stock we'll see how it holds up.
Nice flipper and good longer term prospects - my core accummulated around .43
Still looking to head towards $2.00 by years end (pitch) if market holds together!
GLTA
NMTI is a good "Swing Play"
I am a BUYER at this level.
Could move to $1.60, in advance of EPS results for the QTR,
from the current 0.47c, as of Friday July 16th.
http://stockcharts.com/h-sc/ui?s=NMTI&p=D&yr=1&mn=0&dy=0&id=p43215304291
OOPS!
Posted to the wrong board...still early in Alaska and I need more coffee!!!!!
NMT Medical to Release Second-Quarter 2010 Financial Results on July 29
Date : 07/15/2010 @ 9:15AM
Source : Business Wire
Stock : NMT Medical (NMTI)
http://ih.advfn.com/p.php?pid=nmona&article=43616090&symbol=N^NMTI
NMT Medical, Inc. (NASDAQ: NMTI) today announced that it will release its second-quarter 2010 financial results before the market opens on Thursday, July 29, 2010.
Management will host a conference call at 9:30 a.m. (ET) that morning to review the Company’s financial results and provide a business update. Individuals interested in listening to the live webcast of the conference call should log onto the “Investors” section of NMT’s website, www.nmtmedical.com.
The call also may be accessed by dialing (877) 407-5790 or (201) 689-8328. For interested individuals unable to join the live conference call, a webcast replay will be available on the Company’s website for one year.
About NMT Medical, Inc.
NMT Medical is an advanced medical technology company that designs, develops, manufactures and markets proprietary implant technologies that allow interventional cardiologists to treat structural heart disease through minimally invasive, catheter-based procedures. NMT is currently investigating the potential connection between a common heart defect that allows a right-to-left shunt or flow of blood through a defect like a patent foramen ovale (PFO) and brain attacks such as embolic stroke, transient ischemic attacks (TIAs) and migraine headaches. A common right-to-left shunt can allow venous blood, unfiltered and unmanaged by the lungs, to enter the arterial circulation of the brain, possibly triggering a cerebral event or brain attack. More than 33,000 PFOs have been treated globally with NMT's minimally invasive, catheter-based implant technology.
For more information about NMT Medical, please visit www.nmtmedical.com.
None that I've found - some nice buys today is all I see....
Followers
|
16
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
296
|
Created
|
04/29/08
|
Type
|
Free
|
Moderators |
NMT Medical Announces First-Quarter 2008 Financial Results
Tuesday May 6, 7:30 am ET
For the first quarter of 2008, NMT reported a net loss of approximately $3.9 million, or $0.30 per share. This compares with a net loss of approximately $336,000, or $0.03 per share, for the comparable period in 2007.
27 Wormwood street
Boston, MA 02210-1625
United States - Map
Phone: 617-737-0930
Fax: 617-737-0924
Web Site: http://www.nmtmedical.com
DETAILS
Index Membership: N/A
Sector: Healthcare
Industry: Medical Instruments & Supplies
Full Time Employees: 118
BUSINESS SUMMARY
NMT Medical, Inc., a medical technology company, engages in the design, development, manufacture, and marketing of proprietary implant technologies that allow interventional cardiologists to treat cardiac structural heart disease through minimally invasive, catheter-based procedures.
Technology Overview http://www.nmtmedical.com/technology.aspx?id=206
Its products primarily include CardioSEAL, a cardiac septal repair implant device used for the repair of structural heart disease and intracardiac shunts that result in abnormal blood flow through the chambers of the heart; STARFlex, which incorporates a self-centering system that allows the implant to self-adjust to variations in the anatomy of a septal defect without deforming the septum or interfering with heart valve function; and BioSTAR, a bioabsorbable PFO implant and biological closure technology.
The company also develops BioTREK, which incorporates a unique biosynthetic material that uses the body's own regenerative capability to restore function naturally.
NMT Medical's customers include hospitals, clinics, and other healthcare centers. It markets its product CardioSEAL through its direct sales force to customers in the United States and Canada; and CardioSEAL, STARFlex, and BioSTAR directly in European markets, as well as through selected distributors in the other parts of Europe. The company was founded in 1986 and is headquartered in Boston, Massachusetts.
NMT Medical is currently investigating the potential connection between a common heart defect that allows a right to left shunt or flow of blood through a defect like a patent foramen ovale (PFO) and brain attacks such as embolic stroke, transient ischemic attacks (TIAs) and migraine headaches. A common right to left shunt can allow venous blood, unfiltered and unmanaged by the lungs, to enter the arterial circulation of the brain, possibly triggering a cerebral event or brain attack. More than 27,000 PFOs have been treated globally with NMT's minimally invasive, catheter-based implant technology. NMT Medical was founded in 1986 and is headquartered in Boston, Massachusetts.
Stroke Opportunity
PFO has been implicated as a possible risk factor of embolic stroke and TIA, for which current treatments include lifelong drug therapy or open heart surgery. NMT estimates the worldwide market for stroke- and TIA-related PFO closure procedures at 250,000 annually.
Migraine Opportunity
Medical research suggests that PFO may be a factor in certain migraine headaches. Of the 30 million migraine sufferers in America, those who experience aura and have a PFO may represent up to a 1.5 million patient subset. This represents NMT’s U.S. target market.
KEY EXECUTIVES
Mr. John Ahern , 63
Chief Exec. Officer, Pres
Mr. Richard E. Davis , 49
Chief Financial Officer, Principal Accounting Officer, Exec. VP and Sec.
Mr. Brad Ryno ,
VP of Worldwide Sales
Mr. Geoff Fournie ,
VP of Clinical Devel. for Europe
Shares
12.97 m
Float
12.6 mil
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |